Justin F Gainor
Justin F Gainor is an expert in Oncology at Massachusetts General Hospital (United States). As of October 2026, ScienceLeadR ranks Justin F Gainor in the top 1% of experts worldwide for Thoracic Neoplasms, Lung Neoplasms and Bronchial Neoplasms. Justin F Gainor has authored 450 publications, the most recent in 2026, and is an investigator in 26 clinical trials, 2 of them ongoing. SLR score: 2,192 (community average: 125). How the SLR is computed.
LeadR Profile
Oncology
Subspecialties: Pulmonology - Immunology - Radiotherapy
Main Topics
Publications and Clinical Studies
Profile data updated on
Expert Rankings
Top experts on the MeSH terms this expert works on
Organizations
Career arc: 2012 - 2026
Number : 450
Citations
Best Journals
Breakdown by type
Click a legend label to hide or show it in the chart.
Latest Publications
5 most recent indexed articles
Source: Pubmed
| Title | Journal | Year | Citations |
|---|---|---|---|
| Correction: Unlocking the potential of immunotherapy for patients with resectable non-small cell lung cancer. PMID 42856942 — cells, lung, neoplasms, carcinoma, non-small-cell lung, immunotherapy, lung neoplasms, small cell lung carcinoma | Front Oncol | 2026 | 0 |
| Study Designs for INTerpath-002 and INTerpath-009 of Adjuvant Intismeran Autogene Plus Pembrolizumab for Non-Small Cell Lung Cancer. PMID 42719123 — cells, lung, neoplasms, carcinoma, non-small-cell lung, drug therapy, lung neoplasms, small cell lung carcinoma, therapeutics, chemotherapy | Ann Thorac Surg Short Rep | 2026 | 1 |
| Small Cell Lung Cancer Transformation in Actionable Genomic Alteration-Negative Non-Small Cell Lung Cancer With Response to Tarlatamab: A Case Report. PMID 42696690 — cells, lung, neoplasms, carcinoma, non-small-cell lung, lung neoplasms, small cell lung carcinoma, precision medicine | JCO Precis Oncol | 2026 | 0 |
| Regulatory Perspectives in Precision Oncology: Challenges and Opportunities for Tyrosine Receptor Kinase (NTRK) Inhibitors in Non-small Cell Lung Cancer (NSCLC). PMID 42592642 — cells, research design, genes, lung, neoplasms, carcinoma, non-small-cell lung, lung neoplasms, small cell lung carcinoma, tyrosine, therapeutics | Cureus | 2026 | 0 |
| Navigating NTRK in Non-small Cell Lung Cancer (NSCLC): A Patient Perspective. PMID 42495470 — cells, research design, lung, communication, neoplasms, carcinoma, non-small-cell lung, biomarkers, lung neoplasms, small cell lung carcinoma, diagnosis, therapeutics | Cureus | 2026 | 0 |
Clinical Studies 26
Synthesis
By phase:
By status:
By type:
By Monocentric/Multicentric:
Cohort/Consortium Investigators 4
Ongoing Clinical Trials
2 ongoing trials started since 2021, where this expert is an investigator
Source: ClinicalTrials
| Study | Phase | Status | Start |
|---|---|---|---|
| Study of STK 012 Alone and With Other Treatments in Patients With Advanced Lung Cancer and Other Cancers NCT05098132 — cells, pemetrexed, lung, neoplasms, carcinoma, non-small-cell lung, drug therapy, lung neoplasms, small cell lung carcinoma, interleukin-2, antibodies, monoclonal, therapeutics, carboplatin, chemotherapy, carcinoma | Phase 1/Phase 2 | Recruiting | 2022 |
| Immune and Genomic Markers in ALK NSCLC NCT04881916 — cells, genes, lung, lymphoma, neoplasms, carcinoma, non-small-cell lung, lung neoplasms, small cell lung carcinoma, anaplastic lymphoma kinase, carcinoma | N/A | Active not recruiting | 2021 |
LeadR Networks
Main global connection map